Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Current concepts: host–pathogen interactions in cystic fibrosis airways disease

Anthony C. Tang, Stuart E. Turvey, Marco P. Alves, Nicolas Regamey, Burkhard Tümmler, Dominik Hartl
European Respiratory Review 2014 23: 320-332; DOI: 10.1183/09059180.00006113
Anthony C. Tang
1Dept of Pediatrics, British Columbia Children’s Hospital, Vancouver, British Columbia, Canada. 2Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada. 3Division of Pediatric Respiratory Medicine, University Hospital, Bern, Switzerland. 4Clinical Research Group, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hanover Medical School, Hanover, Germany. 5Cystic Fibrosis Research Group, Dept of Pediatrics I, University of Tübingen, Tübingen, Germany. 6Both authors contributed equally.
1Dept of Pediatrics, British Columbia Children’s Hospital, Vancouver, British Columbia, Canada. 2Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada. 3Division of Pediatric Respiratory Medicine, University Hospital, Bern, Switzerland. 4Clinical Research Group, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hanover Medical School, Hanover, Germany. 5Cystic Fibrosis Research Group, Dept of Pediatrics I, University of Tübingen, Tübingen, Germany. 6Both authors contributed equally.
1Dept of Pediatrics, British Columbia Children’s Hospital, Vancouver, British Columbia, Canada. 2Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada. 3Division of Pediatric Respiratory Medicine, University Hospital, Bern, Switzerland. 4Clinical Research Group, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hanover Medical School, Hanover, Germany. 5Cystic Fibrosis Research Group, Dept of Pediatrics I, University of Tübingen, Tübingen, Germany. 6Both authors contributed equally.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart E. Turvey
1Dept of Pediatrics, British Columbia Children’s Hospital, Vancouver, British Columbia, Canada. 2Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada. 3Division of Pediatric Respiratory Medicine, University Hospital, Bern, Switzerland. 4Clinical Research Group, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hanover Medical School, Hanover, Germany. 5Cystic Fibrosis Research Group, Dept of Pediatrics I, University of Tübingen, Tübingen, Germany. 6Both authors contributed equally.
1Dept of Pediatrics, British Columbia Children’s Hospital, Vancouver, British Columbia, Canada. 2Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada. 3Division of Pediatric Respiratory Medicine, University Hospital, Bern, Switzerland. 4Clinical Research Group, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hanover Medical School, Hanover, Germany. 5Cystic Fibrosis Research Group, Dept of Pediatrics I, University of Tübingen, Tübingen, Germany. 6Both authors contributed equally.
1Dept of Pediatrics, British Columbia Children’s Hospital, Vancouver, British Columbia, Canada. 2Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada. 3Division of Pediatric Respiratory Medicine, University Hospital, Bern, Switzerland. 4Clinical Research Group, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hanover Medical School, Hanover, Germany. 5Cystic Fibrosis Research Group, Dept of Pediatrics I, University of Tübingen, Tübingen, Germany. 6Both authors contributed equally.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco P. Alves
1Dept of Pediatrics, British Columbia Children’s Hospital, Vancouver, British Columbia, Canada. 2Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada. 3Division of Pediatric Respiratory Medicine, University Hospital, Bern, Switzerland. 4Clinical Research Group, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hanover Medical School, Hanover, Germany. 5Cystic Fibrosis Research Group, Dept of Pediatrics I, University of Tübingen, Tübingen, Germany. 6Both authors contributed equally.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Regamey
1Dept of Pediatrics, British Columbia Children’s Hospital, Vancouver, British Columbia, Canada. 2Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada. 3Division of Pediatric Respiratory Medicine, University Hospital, Bern, Switzerland. 4Clinical Research Group, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hanover Medical School, Hanover, Germany. 5Cystic Fibrosis Research Group, Dept of Pediatrics I, University of Tübingen, Tübingen, Germany. 6Both authors contributed equally.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Burkhard Tümmler
1Dept of Pediatrics, British Columbia Children’s Hospital, Vancouver, British Columbia, Canada. 2Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada. 3Division of Pediatric Respiratory Medicine, University Hospital, Bern, Switzerland. 4Clinical Research Group, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hanover Medical School, Hanover, Germany. 5Cystic Fibrosis Research Group, Dept of Pediatrics I, University of Tübingen, Tübingen, Germany. 6Both authors contributed equally.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominik Hartl
1Dept of Pediatrics, British Columbia Children’s Hospital, Vancouver, British Columbia, Canada. 2Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada. 3Division of Pediatric Respiratory Medicine, University Hospital, Bern, Switzerland. 4Clinical Research Group, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hanover Medical School, Hanover, Germany. 5Cystic Fibrosis Research Group, Dept of Pediatrics I, University of Tübingen, Tübingen, Germany. 6Both authors contributed equally.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Dominik.Hartl@med.uni-tuebingen.de
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Host–pathogen interactions in cystic fibrosis (CF). This figure illustrates a few of the various interactions between bacterial, viral and fungal pathogens and the CF host. a) Chronically infecting strains of Pseudomonas aeruginosa frequently acquire hypermutable phenotypes through mismatch repair deficiency, encouraging antibiotic resistance and adapted virulence. Inflammatory responses are modulated through changes in lipid A structure and flagellin expression. This provides resistance to host antimicrobial peptides (AMP) and alters CXCL8 production through Toll-like receptor (TLR)4. Loss of motility/changes in flagellin expression can occur in order to evade recognition by TLR5 and phagocytosis by alveolar macrophages. The presence of flagellin can also induce development of myeloid-derived suppressor cells (MDSCs) leading to suppression of T-cell responses. b) Rhinoviral infection may increase expression of cellular adhesion molecules, such as carcinoembryonic antigen-related cell adhesion molecules (CEACAMs), and enhance attachment of bacterial pathogens to host cells. c) Decreased uptake of Aspergillus fumigatus conidia by cystic fibrosis transmembrane conductance regulator (CFTR)-deficient epithelial cells results in reduced clearance and increased cell death. Germination from spore to hyphal form results in increased inflammatory responses. Bronchial epithelial cells induce T-cell-mediated T-helper cell (Th)2 and Th17 responses complicit in allergic bronchopulmonary aspergillosis. This may be further enhanced by A. fumigatus mediated downregulation of the vitamin D receptor (VDR) and increased interleukin (IL)-5/IL-13 production by gliotoxin.

Tables

  • Figures
  • Table 1. Summary of factors contributing to infection and pulmonary decline in cystic fibrosis
    Lung environment
        Defective cilia function
        Increased mucus viscosity, hypoxia
        Free nutrients: amino acids, iron
        Damage to lung architecture: TGF-β, matrix metalloproteases, neutrophil elastase, oxidant/antioxidant imbalance
        Altered pH
    Immune dysfunction
        Defective and/or decreased antimicrobials: lysozyme, lactoferrin, β-defensins, pentraxin-3, thiocyanate, nitric oxide, surfactant protein D
        Th2 and Th17 responses
        Ineffective cellular mediators: neutrophil accumulation and dysfunction
    Microbial factors
        Changes in virulence: lipid A structure, flagellin expression, loss of quorum sensing, acquisition of a persistent phenotype and hypermutation
        Biofilm formation
        Polymicrobial interaction and secondary infection
        Direct downregulation of antimicrobial pathways: vitamin D receptor downregulation by Aspergillus
    • TGF: transforming growth factor; Th: T-helper cell.

PreviousNext
Back to top
View this article with LENS
Vol 23 Issue 133 Table of Contents
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Current concepts: host–pathogen interactions in cystic fibrosis airways disease
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Current concepts: host–pathogen interactions in cystic fibrosis airways disease
Anthony C. Tang, Stuart E. Turvey, Marco P. Alves, Nicolas Regamey, Burkhard Tümmler, Dominik Hartl
European Respiratory Review Sep 2014, 23 (133) 320-332; DOI: 10.1183/09059180.00006113

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Current concepts: host–pathogen interactions in cystic fibrosis airways disease
Anthony C. Tang, Stuart E. Turvey, Marco P. Alves, Nicolas Regamey, Burkhard Tümmler, Dominik Hartl
European Respiratory Review Sep 2014, 23 (133) 320-332; DOI: 10.1183/09059180.00006113
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Introduction
    • The CF lung microenvironment
    • Infection in CF
    • The inflammatory consequences of dysfunctional immune mechanisms in CF: the example of modifier genes
    • Infections in CF and non-CF lung disease
    • Conclusions and future directions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • CF and non-CF bronchiectasis
  • Epidemiology, occupational and environmental lung disease
  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Unsupervised home spirometry versus supervised clinic spirometry for respiratory disease
  • Peripheral blood monocyte count and outcomes in patients with ILD
  • Effects of CPAP therapy on glucose metabolism in patients with OSA and type 2 diabetes
Show more Reviews

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2023 by the European Respiratory Society